Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity.

Suppr

超能文献

作者信息

Morgan L R, Donley P J, Harrison E F, Hunter H L

出版信息

Eur J Cancer Clin Oncol. 1982 Jan;18(1):113-4. doi: 10.1016/0277-5379(82)90035-9.

DOI:10.1016/0277-5379(82)90035-9

PMID:7200891

Abstract

摘要

相似文献

Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity.

Eur J Cancer Clin Oncol. 1982 Jan;18(1):113-4. doi: 10.1016/0277-5379(82)90035-9.

The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.

Semin Oncol. 1982 Dec;9(4 Suppl 1):71-4.

Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.

Semin Oncol. 1983 Mar;10(1 Suppl 1):62-5.

Prophylaxis of ifosfamide toxicity with oral acetylcysteine.

Semin Oncol. 1983 Mar;10(1 Suppl 1):66-71.

Cyclophosphamide and ifosfamide: role of uroprotective agents.

Cancer Invest. 1990;8(2):269. doi: 10.3109/07357909009017581.

The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.

J Clin Oncol. 1987 May;5(5):799-803. doi: 10.1200/JCO.1987.5.5.799.

N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.

Semin Oncol. 1983 Mar;10(1 Suppl 1):72-5.

Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.

Vet Hum Toxicol. 1981;23(Suppl 1):12-4.

[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].

Schweiz Med Wochenschr. 1979 Dec 8;109(47):1885-7.

[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].

Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 1):403-6.

引用本文的文献

Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats.

Free Radic Biol Med. 2017 Jan;102:274-286. doi: 10.1016/j.freeradbiomed.2016.11.046. Epub 2016 Nov 28.

The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.

PLoS One. 2013 Jun 20;8(6):e66388. doi: 10.1371/journal.pone.0066388. Print 2013.

Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Cancer Invest. 2011 Dec;29(10):655-67. doi: 10.3109/07357907.2011.626479.

VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Cancer Chemother Pharmacol. 1986;18 Suppl 2:S45-50. doi: 10.1007/BF00647451.

Clinical pharmacokinetics of N-acetylcysteine.

Clin Pharmacokinet. 1991 Feb;20(2):123-34. doi: 10.2165/00003088-199120020-00004.

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Invest New Drugs. 1992 Aug;10(3):159-63. doi: 10.1007/BF00877240.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验